Altis Labs
Enabling smaller, faster, and more successful clinical trials with AI.
Est 2019
Enabling smaller, faster, and more successful clinical trials with AI.
Published Sep 17, 2026
| Starting Price | Not public (sales-led) | Sales-led (varies by program) | Sales-led (enterprise) |
| Best For | Oncology trials with CT imaging focus; teams seeking prognostic imaging biomarkers and treatment-effect quantification | Imaging biomarker extraction and radiomics pipelines; imaging-centric research programs | Federated learning and multimodal modeling collaborations; RWE and modeling partnerships |
| Key Strength | Emphasis on prognostication from longitudinal CT imaging and output framing for trial decision-making | Breadth of imaging analytics and established radiomics workflows | Federated learning and multimodal modeling capabilities; partnerships across pharma and health systems |
| Key Weakness | Limited public independent reviews; limited public security/compliance documentation; potential integration burden | May be more imaging-analytics oriented rather than trial endpoint decisioning; implementation complexity | May require substantial data-partnering effort and is not always a drop-in imaging workflow tool |
—